IL15 has entered the clinical trial in patients with metastatic melanoma, renal cell carcinoma, and non-small cell lung cancer in CAR-T therapy and combination treatment with anti-PD1 antibody (96, 97, 128). The gene discussed is IL15; the disease is renal cell carcinoma.